Number of platelet transfusions per participant up to 30 days from study entry · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Thromboembolic events · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Number of participants with at least 1 bleeding episode · people with haematological disorders undergoing intensive chemotherapy or stem cell transplantation
It is very uncertain whether the intervention changes number of participants with at least 1 bleeding episode (very low certainty).
1 finding from 1 review
Mortality (12 months) · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
Plerixafor showed no clear difference in mortality (12 months) compared with placebo (moderate certainty).
1 finding from 1 review
Quality of life · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Progression‐free survival · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to engraftment · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of transplanted participants · People with haematopoietic stem cell mobilisation for autologous transplantation in malignant lymphoma or multiple myeloma
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Number of participants with at least 1 bleeding episode · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Bleeding: Number of days on which a significant bleeding event occurred3 · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of participants with severe or life‐threatening bleeding · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
Therapeutic or non‐prophylactic platelet transfusion showed no clear difference in number of participants with severe or life‐threatening bleeding up… compared with prophylactic platelet transfusion (low certainty).
1 finding from 1 review
Time to first bleeding episode (days) · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Mortality from all causes up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Number of platelet transfusions per participant up to 30 days from study entry · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Quality of life ‐ not reported · patients with haematological disorders undergoing myelosuppressive chemotherapy or stem cell transplantation
1 finding from 1 review
Overall survival · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in overall survival compared with methotrexate (low certainty).
1 finding from 1 review
Prevention of acute GVHD grade II to IV · people receiving allogeneic hematopoietic stem cell transplantation
It is very uncertain whether mycophenolate mofetil changes prevention of acute GVHD grade II to IV compared with methotrexate (very low certainty).
1 finding from 1 review
Relapse · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in incidence of relapse compared with methotrexate (low certainty).
1 finding from 1 review
Nonrelapse mortality · people receiving allogeneic hematopoietic stem cell transplantation
Mycophenolate mofetil showed no clear difference in nonrelapse mortality compared with methotrexate (low certainty).
1 finding from 1 review